Gilberto Lopes (Sylvester Comprehensive Cancer Center at the University of Miami), met in Chicago, talks about results of pembrolizumab vs platinum-based chemotherapy as first-line treatment for advanced/metastatic non–small cell lung cancer with a PD-L1 tumor proportion score ≥ to 1%.